| Literature DB >> 15340404 |
Abstract
Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15340404 DOI： 10.1038/nm0904-887
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440